Reported Earnings • May 31
Full year 2026 earnings released: EPS: ₹0.25 (vs ₹0.83 in FY 2025) Full year 2026 results: EPS: ₹0.25 (down from ₹0.83 in FY 2025). Revenue: ₹629.4m (up 70% from FY 2025). Net income: ₹4.48m (down 55% from FY 2025). Profit margin: 0.7% (down from 2.7% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year and the company’s share price has also fallen by 29% per year. New Risk • May 27
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Market cap is less than US$10m (₹496.4m market cap, or US$5.18m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.3% average weekly change). Revenue is less than US$5m (₹458m revenue, or US$4.8m). Tillkännagivande • May 21
Bandaram Pharma Packtech Limited to Report Q4, 2026 Results on May 30, 2026 Bandaram Pharma Packtech Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026 New Risk • May 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Market cap is less than US$10m (₹370.0m market cap, or US$3.87m). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.6% average weekly change). Revenue is less than US$5m (₹458m revenue, or US$4.8m). Valuation Update With 7 Day Price Move • May 11
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹28.65, the stock trades at a trailing P/E ratio of 38x. Average trailing P/E is 23x in the Forestry industry in India. Total returns to shareholders of 8.5% over the past three years. Valuation Update With 7 Day Price Move • Apr 08
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹27.15, the stock trades at a trailing P/E ratio of 36x. Average trailing P/E is 26x in the Forestry industry in India. Total returns to shareholders of 7.9% over the past three years. Reported Earnings • Feb 16
Third quarter 2026 earnings released: EPS: ₹0.11 (vs ₹0.06 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.11 (up from ₹0.06 in 3Q 2025). Revenue: ₹148.4m (up 61% from 3Q 2025). Net income: ₹1.92m (up 168% from 3Q 2025). Profit margin: 1.3% (up from 0.8% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Feb 03
Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Feb 13, 2026 Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results on Feb 13, 2026 Valuation Update With 7 Day Price Move • Jan 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹31.39, the stock trades at a trailing P/E ratio of 64x. Average trailing P/E is 38x in the Forestry industry in India. Total returns to shareholders of 31% over the past three years. Valuation Update With 7 Day Price Move • Dec 18
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹26.53, the stock trades at a trailing P/E ratio of 54.1x. Average trailing P/E is 38x in the Forestry industry in India. Total returns to shareholders of 11% over the past three years. New Risk • Nov 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Share price has been highly volatile over the past 3 months (9.9% average weekly change). Market cap is less than US$10m (₹396.0m market cap, or US$4.43m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (1.5% net profit margin). Revenue is less than US$5m (₹403m revenue, or US$4.5m). Valuation Update With 7 Day Price Move • Nov 27
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹33.00, the stock trades at a trailing P/E ratio of 67.3x. Average trailing P/E is 29x in the Forestry industry in India. Total returns to shareholders of 171% over the past three years. Reported Earnings • Nov 15
Second quarter 2026 earnings released Second quarter 2026 results: EPS: ₹0.03. Revenue: ₹137.3m (up 93% from 2Q 2025). Net income: ₹331.0k (down 95% from 2Q 2025). Profit margin: 0.2% (down from 9.5% in 2Q 2025). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Nov 10
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹27.49, the stock trades at a trailing P/E ratio of 39.3x. Average trailing P/E is 35x in the Forestry industry in India. Total loss to shareholders of 39% over the past year. Tillkännagivande • Nov 08
Bandaram Pharma Packtech Limited to Report Q3, 2026 Results on Nov 13, 2025 Bandaram Pharma Packtech Limited announced that they will report Q3, 2026 results at 12:15 PM, Indian Standard Time on Nov 13, 2025 Board Change • Sep 11
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Mounika Pammi was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Declared Dividend • Sep 08
Dividend of ₹0.10 announced Dividend of ₹0.10 is the same as last year. Ex-date: 22nd September 2025 Payment date: 28th October 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (12% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 2 years but payments have been stable during that time. Earnings per share has grown by 37% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Tillkännagivande • Sep 05
Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 29, 2025 Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 29, 2025, at 11:00 Indian Standard Time. Reported Earnings • Aug 15
First quarter 2026 earnings released: EPS: ₹0.01 (vs ₹0.15 in 1Q 2025) First quarter 2026 results: EPS: ₹0.01 (down from ₹0.15 in 1Q 2025). Revenue: ₹81.0m (down 29% from 1Q 2025). Net income: ₹247.0k (down 86% from 1Q 2025). Profit margin: 0.3% (down from 1.6% in 1Q 2025). The decrease in margin was driven by lower revenue. Tillkännagivande • Aug 09
Bandaram Pharma Packtech Limited to Report Q1, 2026 Results on Aug 14, 2025 Bandaram Pharma Packtech Limited announced that they will report Q1, 2026 results on Aug 14, 2025 Tillkännagivande • Jul 21
Bandaram Pharma Packtech Limited Appoints Mounika Pammi as Independent Director Bandaram Pharma Packtech Limited at its EGM held on July 21, 2025 announced the appointment of Mrs. Mounika Pammi (Din: 11111376) as an independent director of the company. Tillkännagivande • Jun 20
Bandaram Pharma Packtech Limited Approves the Resignation of Prateek Vijayvargiya as Independent Director, Effective from June 20, 2025 Bandaram Pharma Packtech Limited at its board meeting held on June 20, 2025, approved the resignation of Mr. Prateek Vijayvargiya, Independent Director of the Company effective from June 20, 2025, due to his professional commitments. He has confirmed that there are no other material reasons for his resignation other than that mentioned in his resignation letter. Reported Earnings • Jun 02
Full year 2025 earnings released: EPS: ₹0.83 (vs ₹0.79 in FY 2024) Full year 2025 results: EPS: ₹0.83 (up from ₹0.79 in FY 2024). Revenue: ₹370.6m (up 8.7% from FY 2024). Net income: ₹9.94m (up 4.9% from FY 2024). Profit margin: 2.7% (down from 2.8% in FY 2024). The decrease in margin was driven by higher expenses. New Risk • May 27
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹464.4m market cap, or US$5.44m). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.0% net profit margin). Revenue is less than US$5m (₹421m revenue, or US$4.9m). Valuation Update With 7 Day Price Move • Apr 11
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹37.24, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 22x in the Forestry industry in India. Total returns to shareholders of 12% over the past year. Reported Earnings • Feb 19
Third quarter 2025 earnings released: ₹0.01 loss per share (vs ₹0.46 profit in 3Q 2024) Third quarter 2025 results: ₹0.01 loss per share (down from ₹0.46 profit in 3Q 2024). Revenue: ₹100.0m (up 2.1% from 3Q 2024). Net loss: ₹134.0k (down 102% from profit in 3Q 2024). New Risk • Feb 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (27% accrual ratio). Market cap is less than US$10m (₹529.2m market cap, or US$6.09m). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹356m revenue, or US$4.1m). Valuation Update With 7 Day Price Move • Nov 28
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹50.38, the stock trades at a trailing P/E ratio of 37.7x. Average trailing P/E is 27x in the Forestry industry in India. Total returns to shareholders of 65% over the past year. Valuation Update With 7 Day Price Move • Oct 10
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₹49.01, the stock trades at a trailing P/E ratio of 54.9x. Average trailing P/E is 33x in the Forestry industry in India. Total returns to shareholders of 68% over the past year. Tillkännagivande • Sep 13
Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2024 Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2024, at 11:00 Indian Standard Time. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹37.96, the stock trades at a trailing P/E ratio of 42.5x. Average trailing P/E is 34x in the Forestry industry in India. Total returns to shareholders of 37% over the past year. Declared Dividend • Sep 07
Dividend of ₹0.10 announced Dividend of ₹0.10 is the same as last year. Ex-date: 20th September 2024 Payment date: 27th October 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (12% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 56% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Tillkännagivande • Sep 04
Bandaram Pharma Packtech Limited Proposes Final Dividend for the Financial Year 2023-24 Bandaram Pharma Packtech Limited announced that the Board of Directors at its meeting held on September 04, 2024 considered to pay Dividend of INR 0.10 per share to the shareholders, subject to approval of shareholders for the Financial Year 2023-24. Valuation Update With 7 Day Price Move • Aug 27
Investor sentiment improves as stock rises 40% After last week's 40% share price gain to ₹42.44, the stock trades at a trailing P/E ratio of 47.5x. Average trailing P/E is 34x in the Forestry industry in India. Total returns to shareholders of 53% over the past year. Reported Earnings • Aug 17
First quarter 2025 earnings released First quarter 2025 results: EPS: ₹0.15. Revenue: ₹113.7m (up 94% from 1Q 2024). Net income: ₹1.78m (up 139% from 1Q 2024). Profit margin: 1.6% (up from 1.3% in 1Q 2024). The increase in margin was driven by higher revenue. Tillkännagivande • Aug 07
Bandaram Pharma Packtech Limited to Report Q1, 2025 Results on Aug 13, 2024 Bandaram Pharma Packtech Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Tillkännagivande • Jul 12
Bandaram Pharma Packtech Limited Announces of Demise Bhandaram Muniratnam Reddy as Promoter/ Chairman & Non-Executive Director Bandaram Pharma Packtech Limited announced sudden and untimely demise of Mr. Bhandaram Muniratnam Reddy (DIN: 09487708), Promoter/Chairman & Non-Executive Director of the Company on late hours of July 11, 2024. As an interim arrangement, the Management Team & Board of Directors shall continue the operations of the Company seamlessly. Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: ₹0.82 (vs ₹0.86 in FY 2023) Full year 2024 results: EPS: ₹0.82. Revenue: ₹341.1m (up 82% from FY 2023). Net income: ₹9.68m (up 276% from FY 2023). Profit margin: 2.8% (up from 1.4% in FY 2023). The increase in margin was driven by higher revenue. Tillkännagivande • May 17
Bandaram Pharma Packtech Limited to Report Q4, 2024 Results on May 29, 2024 Bandaram Pharma Packtech Limited announced that they will report Q4, 2024 results on May 29, 2024 Valuation Update With 7 Day Price Move • Apr 01
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₹35.21, the stock trades at a trailing P/E ratio of 44.7x. Average trailing P/E is 17x in the Forestry industry in India. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹35.66, the stock trades at a trailing P/E ratio of 45.3x. Average trailing P/E is 17x in the Forestry industry in India. Total returns to shareholders of 41% over the past year. Board Change • Jan 29
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Jan 01
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Oct 29
Bandaram Pharma Packtech Limited to Report Q2, 2024 Results on Nov 14, 2023 Bandaram Pharma Packtech Limited announced that they will report Q2, 2024 results on Nov 14, 2023 Tillkännagivande • Oct 18
Bandaram Pharma Packtech Limited Approves Appointment of Priyanka Agarwal as an Additional Director (Independent Category) Bandaram Pharma Packtech Limited announced that at its board meeting held on October 17, 2023, approved the appointment of Ms. Priyanka Agarwal as an additional director (Independent category) of the company with effect from October 17, 2023. She is a Commerce Graduate and also completed executive course of ICSI. Tillkännagivande • Sep 03
Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2023 Bandaram Pharma Packtech Limited, Annual General Meeting, Sep 27, 2023. Tillkännagivande • Sep 02
Bandaram Pharma Packtech Limited Approves Management Changes Bandaram Pharma Packtech Limited at its Board meeting held on September 01, 2023 approved Appointment of Ms. Neha Kankariya as Company Secretary and Compliance Officer of theCompany with effect from, September 01, 2023. Ms. Neha Kankariya is a qualified Company Secretary having experience of more than 5 years in Listed Companies and having soundexposure in secretarial and legal matters. Resignation of Ms. Aakanksha as an Independent Director of the Company with effect from, September 01, 2023. Appointment of Mr. Suman Mallu as an Additional Director of the Company with effect from, September 01, 2023 in Independent category. Mr. Suman Mallu is a senior architect in Bosch Limited an automotive Industry. He is having a rich experience of more than 14 years in this field. Tillkännagivande • Sep 01
Bandaram Pharma Packtech Limited Announces Resignation of Harish Sharma as Company Secretary and Compliance Officer Bandaram Pharma Packtech Limited announced that Mr. Harish Sharma has resigned from the post of Company Secretary and Compliance officer due to his personal reasons with effect from August 31, 2023 (close of Business hours). Tillkännagivande • Aug 05
Bandaram Pharma Packtech Limited to Report Q1, 2024 Results on Aug 11, 2023 Bandaram Pharma Packtech Limited announced that they will report Q1, 2024 results on Aug 11, 2023 New Risk • Aug 04
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 300% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.8x net interest cover). Shares are highly illiquid. High level of non-cash earnings (41% accrual ratio). Shareholders have been substantially diluted in the past year (300% increase in shares outstanding). Market cap is less than US$10m (₹335.6m market cap, or US$4.05m). Minor Risks Paying a dividend despite having no free cash flows. Revenue is less than US$5m (₹189m revenue, or US$2.3m). Board Change • Jul 24
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Jul 03
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Tillkännagivande • May 31
Bandaram Pharma Packtech Limited Recommends Dividend Bandaram Pharma Packtech Limited recommended a dividend of INR 0.10 (10 paisa) per share subject to approval of members at the upcoming Annual General Meeting. Tillkännagivande • May 26
Bandaram Pharma Packtech Limited to Report Q4, 2023 Results on May 30, 2023 Bandaram Pharma Packtech Limited announced that they will report Q4, 2023 results on May 30, 2023 Board Change • May 08
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Apr 10
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Non-Executive Chairman Bhandaram Reddy is the most experienced director on the board, commencing their role in 2022. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Feb 27
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Additional Independent Director Aakanksha . was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Feb 08
Bandaram Pharma Packtech Limited Announces Executive Changes Bandaram Pharma Packtech Limited announces Change in designation of Mr. B. Muniratnam Reddy from Managing Director to Non-Executive Chairman of the Company. Appointment of Mr. B. Deepak Reddy as Additional director and Managing Director (Executive Category) of the Company. Appointment of Ms. Aakanksha as additional director (Independent Category) of the Company. Tillkännagivande • Jan 25
Bandaram Pharma Packtech Limited to Report Q3, 2023 Results on Feb 01, 2023 Bandaram Pharma Packtech Limited announced that they will report Q3, 2023 results on Feb 01, 2023 Board Change • Nov 22
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Venkata Rajaram Chittuluru was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
